Analyst Mara Goldstein of Mizuho Securities maintained a Buy rating on Fate Therapeutics (FATE – Research Report), with a price target of $12.00.
Mara Goldstein has assigned a Buy rating to Fate Therapeutics due to several reasons. Firstly, Goldstein appears to be encouraged by the latest updates on Fate’s Ono program, specifically the development of FT825/ONO-8250. This is a unique off-the-shelf CAR-T cell product that targets HER2 preferentially and is engineered to enable multi-antigen targeting, improve trafficking, and overcome immunosuppression. The potential of this program to drive Fate’s growth seems to be a significant factor in Goldstein’s positive rating.
Furthermore, Goldstein’s rating appears to be influenced by her interpretation of the recently released SITC titles. The updates provided by these titles were viewed as mostly incremental by Goldstein, suggesting a steady progression in Fate’s overall performance and development. Consequently, Goldstein’s Buy rating seems to be based on a combination of the encouraging updates on Fate’s Ono program and the steady incremental progress indicated by the SITC titles.
FATE’s price has also changed dramatically for the past six months – from $5.480 to $2.100, which is a -61.68% drop .
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Fate Therapeutics (FATE) Company Description:
Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Read More on FATE:
